Cure Today

MDS Treatment Advances: Targeted Therapies and Anemia Management

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...
The American Journal of Managed Care

Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS

A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic ...
Targeted Oncology

Moving Beyond Transfusion Dependence in the MDS Landscape

According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion independence compared with 15.0% of patients treated with placebo. Respondents ...
The American Journal of Managed Care

Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
Business Wire

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Seeking Alpha

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. (KROS) is gearing up to report long-term results from its phase 2 study using KER-050 [elritercept] for the treatment of patients with myelodysplastic syndrome [MDS]. Matter ...
Business Wire

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
ascopubs.org

Target therapy adoption for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): A five-year real-world analysis.

Evidence in real-world settings for multiple primary malignancies in prostate cancer: Comparison with single primary prostate cancers. Is increase in CME consumption associated with practice change in ...
Healthline

Ask the Advocate: How Do You Fight for the Best MDS Treatment on Behalf of Your Loved One?

Social worker Marie Brewer talks about the challenges of supporting a loved one with myelodysplastic syndrome (MDS) and ways to find assistance and treatment options. Myelodysplastic syndromes (MDS) ...
Nasdaq

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including ...
Business Insider

Buy Rating Reaffirmed for Keros Therapeutics as KER-050 Advances Towards Phase 3 for MDS Treatment

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Keros Therapeutics (KROS – Research Report) today and set a price target of $100.00. Andrew Fein has given his Buy rating due to a ...